1
|
John T, Grohe C, Goldman J, De Marinis F, Kato T, Wang Q, Choi JH, Melotti B, Fidler M, Sainsbury L, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst R, Majem Tarruella M. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
2
|
Cappuzzo F, Chiari R, Tiseo M, Minotti V, De Marinis F, Delmonte A, Bungaro M, Cortinovis D, Galetta D, Bonanno L, Chella A, Gridelli C, Morabito A, Grossi F, Bria E, Giannarelli D, Fontanini G, Borra G, Gori S, Mazzoni F, Pilotto S, Landi L. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Lococo F, Chiappetta M, Cancellieri A, Cardillo G, Zanelli F, Mangiameli G, Toschi L, Guggino G, Romano F, Leuzzi G, Proto C, Spaggiari L, De Marinis F, Vita E, Menna E, Margaritora S, Bria E. EP05.03-008 Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Spira A, Lim S, Griesinger F, De Marinis F, Mccarthy T, Huseinovic N, O'Donnell S, Ahn J. P14.07 PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Piccirillo M, Bonanno L, Garassino M, Dazzi C, Cavanna L, Esposito G, Burgio M, Rosetti F, Rizzato S, Arenare L, Gargiulo P, Di Liello R, De Marinis F, Crinò L, Morgillo F, Ciardiello F, Normanno N, Gallo C, Gridelli C, Morabito A. 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1812] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Herbst R, De Marinis F, Giaccone G, Vergnenegre A, Barrios C, Morise M, Felip E, Oprean C, Kim Y, Andric Z, Mocci S, Enquist I, Komatsubara K, Mccleland M, Deng Y, Kuriki H, Villalobos M, Phan S, Spigel D, Jassem J. FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Mazieres J, Veillon R, Felip E, Le X, Garassino M, Stanton T, Morise M, Lee J, Matsumoto S, De Marinis F, Wehler T, Clark A, Friese-Hamin M, Stroh C, Bruns R, Otto G, Paik P. P85.01 Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Wu Y, John T, Grohe C, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.292] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Menis J, Bironzo P, Radj G, Greillier L, Monnet I, Livi L, Young R, Decroisette C, Cloarec N, Robinet G, Schott R, Califano R, De Marinis F, Mauer M, Pochesci A, Silva M, Caramella C, Dingemans AM, Dive C, Besse B. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
10
|
Durante S, Corrao G, Marvaso G, Piperno G, Colombo F, Gugliandolo S, Rondi E, Vigorito S, Frassoni S, Bagnardi V, Fodor C, Spaggiari L, De Marinis F, Orecchia R, Jereczek-Fossa B. PO-1023: Impact of biological features in radiosurgery for Brain metastases from Non Small Cell Lung Cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01040-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Martini G, Bria E, Gridelli C, Garassino M, Ardizzoni A, De Marinis F. 1808TiP Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC): A multicenter, phase IIIb, single arm, safety study (MAURIS trial). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Pagano M, Ceresoli G, Zucali P, Pasello G, Garassino M, Grosso F, Tiseo M, Soto Parra H, Zanelli F, Cappuzzo F, Grossi F, De Marinis F, Pedrazzoli P, C. bonelli, Berselli A, Normanno N, Pinto C. 1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Viteri S, Mazieres J, Veillon R, Felip E, Le X, Garassino M, Stanton T, Morise M, Lee JS, Matsumoto S, De Marinis F, Wehler T, Clark A, Friese-Hamim M, Stroh C, Bruns R, Otto G, Paik P. 1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1600] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Besse B, Menis J, Bironzo P, Gervais R, Greillier L, Monnet I, Livi L, Young R, Decroisette C, Cloarec N, Robinet G, Schott R, Califano R, De Marinis F, Banna G, Mauer M, Pochesci A, Hasan B, Berghmans T, Dingemans AM. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2327] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Francia CM, Marvaso G, Piperno G, Gandini S, Ferrari A, Zerella MA, Arculeo S, Sibio D, Fodor C, Pepa M, Trivellato S, Rondi E, Vigorito S, Cattani F, Spaggiari L, De Marinis F, Orecchia R, Ciardo D, Jereczek-Fossa BA. Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series. Neoplasma 2020; 67:684-691. [PMID: 32182088 DOI: 10.4149/neo_2020_190717n645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Accepted: 09/29/2019] [Indexed: 11/08/2022]
Abstract
CyberKnife® Lung Optimized Treatment (LOT) allows the treatment of lung cancer without invasive fiducial implantation. The aim of this retrospective analysis was to evaluate the feasibility, toxicity and clinical outcome. One hundred fifteen patients (124 lesions) were treated with CyberKnife® using LOT. The median age was 72.6 years (range 31.8-90.3). From 124 treated lesions, 52 were with histopathological confirmation (41 primitive pulmonary cancers, 8 pulmonary metastases) and 72 as untyped tumors. For 5 patients (6 lesions) treatment was an in-field re-irradiation. Concomitant therapy was administered in 7 patients. Zero-View tracking was applied in 69 patients, 1-View in 33 patients, 2-View in 22 patients. The median total dose was 45 Gy (range 18-54), median dose/fraction was 15 Gy (range 4-18) with a median prescription isodose of 80% (range 68-85). The median planning target volume (PTV) was 25 cm3 (range 3-195). The median follow-up was 20 months (range 7-47). Thirty-seven patients (32%) were alive with no evidence of disease, 39 patients (34%) were alive with clinically evident disease, and 38 patients (33%) died of the disease. The 1- and 2-year overall survival (OS) rate was 83% and 61%. The median time to progression was 19 months (95% confidence interval: 11-19 months), 1- and 2-year progression-free survival (PFS) rates were 62% and 41%, respectively. Smaller PTV was significantly associated with better OS, PFS and in-field PFS in univariate and multivariate analyses. Acute toxicity was observed in 36 patients (41%). Late toxicity was registered in 25 patients (29%). G3 late toxicity was observed in one patient (1.1%). Our data suggest that fiducial less-stereotactic body radiation therapy (SBRT) is a feasible, well-tolerated and potentially effective treatment with high compliance in the setting of inoperable patients due to concomitant disease or previous treatments.
Collapse
Affiliation(s)
- C Maria Francia
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Marvaso
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Piperno
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Gandini
- Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - A Ferrari
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - M Alessia Zerella
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - S Arculeo
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - D Sibio
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - C Fodor
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - M Pepa
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Trivellato
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - E Rondi
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Vigorito
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - F Cattani
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - L Spaggiari
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Division of Thoracic Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - F De Marinis
- Division of Thoracic Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - R Orecchia
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Scientific Directorate, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - D Ciardo
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - B Alicja Jereczek-Fossa
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| |
Collapse
|
16
|
Passaro A, De Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa B, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Rosell R, Poltoratskiy A, Hochmair M, Laktionov K, Ramlau R, Garcìa MA, Skrickova J, Piovano P, Rizzato S, Bidoli P, Kowalski D, Clementi L, Cseh A, De Marinis F. A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
D'Arcangelo M, Tassinari D, De Marinis F, Delmonte A, Galetta D, Cecere F, Pilotto S, Zanelli F, Bonanno L, Landi L, D'Incà F, Cappuzzo F. P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1359] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
19
|
De Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D. P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Gadgeel S, Mok T, Peters S, Alexander J, Leighl N, Sriuranpong V, Perol M, De Castro G, Nadal E, De Marinis F, Han JY, Yan M, Riehl T, Schleifman E, Paul S, Mocci S, Shames D, Mathisen M, Dziadziuszko R. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.079] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Passaro A, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D, De Marinis F. Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Karachaliou N, Chaib I, Bracht J, Filipska M, Drozdowskyj A, Cardona A, Vergnenegre A, Sánchez-Torres J, Provencio M, De Marinis F, Carcereny E, Reguart N, García Campelo R, Santarpia M, Viteri S, Bivona T, Rosell R. P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
23
|
Landi L, D'Incà F, Cortesi E, Chiari R, Grossi F, Delmonte A, De Marinis F, Signorelli D, Dazzi C, Sperandi F, Catino A, Giannarelli D, Soto Parra H, Minuti G, Bordi P, Migliorino M, Palla A, Tonini G, Cognetti F, Santoro A, Tassinari D, Scoppola A, Bidoli P, Piantedosi F, Maio M, Crinò L, Cappuzzo F. P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, De Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee J, Calabro L, Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K. OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Clerici M, De Marinis F, Piazza E, Frontini L, Tucci E, Barni S, Bretti S, Luporini G, Intini C. Phase II Study of the Activity and Tolerability of a Combined Regimen of High-Dose Epirubicin and Cisplatin in Stage IIIb and IV Non-Small Cell Lung Cancer. Tumori 2018; 84:669-72. [PMID: 10080674 DOI: 10.1177/030089169808400611] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
AIM To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). METHOD Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. RESULTS A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. CONCLUSIONS This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.
Collapse
Affiliation(s)
- M Clerici
- Medical Oncology Department, Ospedale S. Giuseppe, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mok T, Peters S, Camidge DR, Gadgeel S, Ou S, Kim D, Dziadziuszko R, De Marinis F, Sangha R, Zeaiter A, Noe J, Nueesch E, Liu T, Loftin I, Williams C, Shaw A. JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.314] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Garassino M, Cortesi E, Grossi F, Chiari R, Parra HS, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Gamucci T, Ceresoli G, Antonelli P, Vasile E, Pinto C, Galetta D, Macerelli M, De Marinis F. MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.550] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Wolf J, Han J, Nishio M, Souquet P, Paz-Ares L, De Marinis F, Seto T, De Jonge M, Kim T, Vansteenkiste J, Tan D, Garon E, Groen H, Hochmair M, Felip E, Reguart N, Thomas M, Overbeck T, Ohashi K, Giovannini M, Yura R, Joshi A, Akimov M, Heist R. PS04.06 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.075] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, De Marinis F, Minuti G, Buosi R, Morabito A, Spitaleri G, Gridelli C, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Alì G, Proietti A, Fontanini G, Joseph A, Crinò L, Cappuzzo F. P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Passaro A, Metro G, Tiseo M, Migliorino M, Santo A, Sperandi F, Maione P, Puppo G, Grossi F, Soto Parra H, Borra G, Roca E, Rocco D, Stasi I, Galetta D, Carta A, Milella M, Fasola G, Gebbia V, Ferrari S, De Marinis F. ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Grossi F, Crinò L, Delmonte A, Turci D, Lo Russo G, De Marinis F, Soto Parra H, Galetta D, Cappuzzo F, Sperandi F, Tiseo M, Puppo G, Roila F, Migliorino M, Tonini G, Cognetti F, Santoro A, Tassinari D, Scoppola A, Cortesi E. Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Crinò L, Bidoli P, Roila F, Cortesi E, Garassino M, Cappuzzo F, Grossi F, Tonini G, Sarobba G, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Alfonso I, De Marinis F, Delmonte A. Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Garassino M, Cortesi E, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Gamucci T, Ceresoli G, Antonelli P, Vasile E, Pagano M, Macerelli M, Lagroscino A, De Marinis F. Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
De Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Schuler M, Yang JCH, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016; 27:417-23. [PMID: 26646759 PMCID: PMC4769992 DOI: 10.1093/annonc/mdv597] [Citation(s) in RCA: 110] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Revised: 11/11/2015] [Accepted: 11/23/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy. PATIENTS AND METHODS Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m(2)/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes. RESULTS Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent. CONCLUSION Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy. TRIAL REGISTRATION NUMBER NCT01085136 (clinicaltrials.gov).
Collapse
Affiliation(s)
- M Schuler
- West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen German Cancer Research Center, German Cancer Consortium (DKTK), Heidelberg, Germany
| | - J C-H Yang
- Department of Medical Research, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan
| | - K Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J-H Kim
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - J Bennouna
- Oncologie Médicale, Institut de Cancérologie de l'Ouest, Nantes, France
| | - Y-M Chen
- Taipei Cancer Center, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
| | - C Chouaid
- Services de Pneumologie, CHI Créteil, Créteil, France
| | - F De Marinis
- 1st Oncological Pulmonary Unit, San Camillo, High Specialization Hospital, Rome Thoracic Oncology Division, European Institute of Oncology, Milan, Italy
| | - J-F Feng
- Department of Medical Oncology, Jiangsu Province Cancer Hospital, Nanjing, China
| | - F Grossi
- IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - D-W Kim
- Lung Cancer, Seoul National University Hospital, Seoul, Republic of Korea
| | - X Liu
- Department of Pulmonary Oncology, Affiliated Hospital of Academy of Military Medical Science, Beijing
| | - S Lu
- Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - J Strausz
- Department of Pulmonology, Koranyi National Institute for Pulmonology, Budapest, Hungary
| | - Y Vinnyk
- Abdominal Department, Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine
| | - R Wiewrodt
- Department of Medicine A, University Hospital, Münster, Germany
| | - C Zhou
- Department of Oncology, Tongji University Medical School Cancer Institute, Shanghai, China
| | - B Wang
- Biostatistics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield
| | - V K Chand
- Clinical Development Medical Affairs-Oncology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA
| | - D Planchard
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| |
Collapse
|
36
|
Schuler M, Planchard D, Yang JC, De Marinis F, Bennouna J, Kim JH, Chouaid C, Wiewrodt R, Grossi F, Feng J, Strausz J, Lu S, Kim DW, Liu X, Chen YM, Zhou C, Wang B, Chand VK, Park K. Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung 5 (LL5). Pneumologie 2015. [DOI: 10.1055/s-0035-1544761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Casiraghi M, Solli P, De Marinis F, Petrella F, Guarize J, Spaggiari L. 157-I * SALVAGE SURGERY AFTER DEFINITIVE CHEMORADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu276.157] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Middleton G, Gridelli C, De Marinis F, Pujol J, Reck M, Ramlau R, Parente M, Pieters T, Visseren-Grul C, Antonio BS, John W, Zimmermann A, Chouaki N, Paz-Ares L. Evaluation of Changes in Renal Function in a Phase III Study of Maintenance (Mtc) Pemetrexed (Pem) Plus Best Supportive Care (Bsc) Versus Placebo (Plb) Plus Bsc After Induction Treatment (Tx) with Pem Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer (Paramount). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.36] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Planchard D, Park K, Yang J, Kim J, De Marinis F, Chen Y, Feng J, Chouaid C, Lu S, Wiewrodt R, Zhou C, Bennouna J, Liu X, Lungershausen J, Wang B, Chand V, Schuler M. Patient-Reported Outcomes (Pros) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) Receiving Afatinib (A) Monotherapy Followed By a + Paclitaxel (A + P) Vs Investigator'S Choice of Single-Agent Chemotherapy (Ic): Lux-Lung 5 (Ll5). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.44] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Park K, Kim J, Schuler M, Planchard D, De Marinis F, Chen Y, Zhou C, Bennouna J, Xiaoqing L, Feng J, Bidoli P, Strausz J, Chouaid C, Huang M, Ho L, Wang B, Chand V, Yang J. Afatinib (A) Followed By a + Paclitaxel (P) or Investigator'S Choice of Single-Agent Chemotherapy (Ic) in Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung: Subgroup Analysis of Lux-Lung 5 (Ll5). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.42] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G, Della-Fiorentina S, Begbie S, Jennens R, Dass J, Pittman K, Ivanova N, Koynova T, Petrov P, Tomova A, Tzekova V, Couture F, Hirsh V, Burkes R, Sangha R, Ambrus M, Janaskova T, Musil J, Novotny J, Zatloukal P, Jakesova J, Klenha K, Roubec J, Vanasek J, Fayette J, Barlesi F, Bennouna-Louridi J, Chouaid C, Mazières J, Vallerand H, Robinet G, Souquet PJ, Spaeth D, Schott R, Lena H, Martinet Y, El Kouri C, Baize N, Scherpereel A, Molinier O, Fuchs F, Josten K, Manegold C, Marschner N, Schneller F, Overbeck T, Thomas M, von Pawel J, Reck M, Schuette W, Hagen V, Schneider CP, Georgoulias V, Varthalitis I, Zarogoulidis K, Syrigos K, Papandreou C, Bocskei C, Csanky E, Juhasz E, Losonczy G, Mark Z, Molnar I, Papai-Szekely Z, Tehenes S, Vinkler I, Almel S, Bakshi A, Bondarde S, Maru A, Pathak A, Pedapenki R, Prasad K, Prasad S, Kilara N, Gorijavolu D, Deshmukh C, John S, Sharma L, Amoroso D, Bajetta E, Bidoli P, Bonetti A, De Marinis F, Maio M, Passalacqua R, Cascinu S, Bearz A, Bitina M, Brize A, Purkalne G, Skrodele M, Baba A, Ratnavelu K, Saw M, Samson-Fernando M, Ladrera G, Jassem J, Koralewski P, Serwatowski P, Krzakowski M, Cebotaru C, Filip D, Ganea-Motan D, Ianuli C, Manolescu I, Udrea A, Burdaeva O, Byakhov M, Filippov A, Lazarev S, Mosin I, Orlov S, Udovitsa D, Khorinko A, Protsenko S, Chang A, Lim H, Tan Y, Tan E, Bastus Piulats R, Garcia-Foncillas J, Valdivia J, de Castro J, Domine Gomez M, Kim S, Lee JS, Kim H, Lee J, Shin S, Kim DW, Kim YC, Park K, Chang CS, Chang GC, Goan YG, Su WC, Tsai CM, Kuo HP, Benekli M, Demir G, Gokmen E, Sevinc A, Crawford J, Giaccone G, Haigentz M, Owonikoko T, Agarwal M, Pandit S, Araujo R, Vrindavanam N, Bonomi P, Berg A, Wade J, Bloom R, Amin B, Camidge R, Hill D, Rarick M, Flynn P, Klein L, Lo Russo K, Neubauer M, Richards P, Ruxer R, Savin M, Weckstein D, Rosenberg R, Whittaker T, Richards D, Berry W, Ottensmeier C, Dangoor A, Steele N, Summers Y, Rankin E, Rowley K, Giridharan S, Kristeleit H, Humber C, Taylor P. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80. [DOI: 10.1093/annonc/mdt371] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Obasaju C, Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo T, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann A, Visseren-Grul C, Gridelli C. Maintenance Pemetrexed (PEM) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC after PEM Plus Cisplatin for Advanced Nonsquamous NSCLC. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)31933-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
43
|
Reck M, Paz-Ares L, De Marinis F, Molinier O, Prasad Sahoo T, Laack E, John W, Zimmermann A, Visseren-Grul C, Gridelli C. Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33787-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
44
|
Rosell R, Sureda BM, Costa C, Molina M, Gimenez-Capitan A, Karachaliou N, Wei J, Vergnenegre A, Giannikopoulos P, Mermel C, Bivona T, De Marinis F, Felip E, Bueno TM, Gervais R, Santarpia M, Majem M, Bosch-Barrera J, Garcia-Campelo M, Paz-Ares L. Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34341-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
45
|
Gori B, Del Signore E, Fulvi A, Ricciardi S, Migliorino M, Belli R, Condò S, De Santis S, Colacchi A, De Marinis F. Erlotinib Role in Pretreated Egfr Wild Type Caucasian Patients: A Retrospective Observational Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33808-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
De Marinis F, Rosell R, Vergnenegre A, Massuti B, Felip E, Gervais R, Cardenal F, Garcia-Gomez R, Taron M, Paz-Ares L. 9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72328-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Caffo O, Ceribelli A, De Marinis F, Bulotta A, Novello S, Bearz A, Durante E, Grossi F, Pegoraro M, Tiseo M. 9147 POSTER Treatment and Clinical Outcomes of Young Patients (^40 Years) With Advanced Non-small Cell Lung (NSCLC) – Data From a Retrospective Multicentric Database. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72459-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
48
|
Paz-Ares LG, De Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed SA, John WJ, Chouaki N, Zimmerman A, Visseren Grul CM, Gridelli C. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra7510] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA7510 Background: The PARAMOUNT trial investigated whether pem continuation maintenance therapy improves progression-free survival (PFS) after pem-cisplatin induction therapy in patients (pts) with advanced nonsquamous NSCLC. Methods: In this double-blind, placebo-controlled trial, 939 pts participated in the induction phase, specified as four cycles of induction pem (500 mg/m2) and cisplatin (75 mg/m2) on day 1 of a 21-day cycle. Pts who had not progressed during pem-cisplatin induction and had an Eastern Cooperative Oncology Group performance status (PS) of 0/1 (n=539; 57.4%) were randomized (2:1, stratified for disease stage, PS, and induction response) to maintenance pem (500 mg/m2 on day 1 of a 21-day cycle) plus BSC (n=359) or placebo plus BSC (n=180) until disease progression. All pts received vitamin B12, folic acid, and dexamethasone. The primary endpoint was PFS (target: HR=0.65, two-sided alpha=0.05; 90% power with minimum of 238 events). Results: Pt characteristics were balanced between arms: median age=61 years; 58% male; 95% Caucasian; 32% PS 0; 91% stage IV; 87% adenocarcinoma; and 45% induction complete/partial response. Pem continuation maintenance resulted in a 36% reduction in the risk of progression (HR=0.64, 95% CI: 0.51-0.81; P=0.00025). The median independently reviewed PFS (472 pts, 297 events), measured from randomization, was 3.9 months (95% CI: 3.0-4.2) on the pem arm, and 2.6 months (95% CI: 2.2-2.9) on the placebo arm. The disease control rate (% pts with response/stable disease) was 71.8% on the pem arm, and 59.6% on the placebo arm (P=0.009). The drug-related serious adverse event (AE) rate was 8.9% on the pem arm, and 9.2% of pts had grade 3/4 laboratory Common Toxicity Criteria AEs. On the placebo arm, the rates were 2.8% and 0.6%, respectively. Discontinuations due to AEs were 5.3% on the pem arm, 3.3% on the placebo arm. Conclusions: PARAMOUNT met its primary endpoint and showed that pem continuation maintenance following pem-cisplatin induction is an effective and well tolerated treatment for pts with advanced nonsquamous NSCLC.
Collapse
Affiliation(s)
- L. G. Paz-Ares
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - F. De Marinis
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - M. Dediu
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - M. Thomas
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - J. Pujol
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - P. Bidoli
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - O. Molinier
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - T. P. Sahoo
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - E. Laack
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - M. Reck
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - J. Corral
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - S. A. Melemed
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - W. J. John
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - N. Chouaki
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - A. Zimmerman
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - C. M. Visseren Grul
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| | - C. Gridelli
- Hospital Universitario Virgen del Rocío, Seville, Spain; San Camillo-Forlanini Hospital, Rome, Italy; Medical Oncology Department, Institute of Oncology, Bucharest, Romania; Thoraxklinik at the University of Heidelberg, Heidelberg, Germany; Montpellier University Hospital, Montpellier, France; Az Ospedale S. Gerardo, Monza, Italy; Le Mans Regional Hospital, Le Mans, France; Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India; Ambulantes Krebszentrum Hamburg, Hamburg, Germany; Hospital
| |
Collapse
|
49
|
Ardizzoni A, Boni L, Tiseo M, Vincent A, Passalacqua R, Camerini A, Labianca R, Genestreti G, Zanelli F, Ciuffreda L, Di Costanzo F, De Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Smit EF. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Paz-Ares LG, De Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed SA, John WJ, Chouaki N, Zimmerman A, Visseren Grul CM, Gridelli C. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra7510] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|